← Back to Clinical Trials
Recruiting NCT05655702

NCT05655702 DRug Use & Infections in ViEtnam: TuBerculosis Control

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05655702
Status Recruiting
Phase
Sponsor ANRS, Emerging Infectious Diseases
Condition Tuberculosis
Study Type INTERVENTIONAL
Enrollment 4,000 participants
Start Date 2023-10-02
Primary Completion 2025-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Community based TB intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 4,000 participants in total. It began in 2023-10-02 with a primary completion date of 2025-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overarching purpose of the proposed research is to demonstrate that a targeted, multi-component community-based intervention among PWID in Hai Phong will decrease TB prevalence among this very high-risk population.

Eligibility Criteria

Inclusion Criteria: * 18 years of age or older * Self-declaring injecting heroin or any other drug * Positive urine test for heroin or methamphetamine * Presence of recent injection site marks Exclusion Criteria: * Unable to understand or refused to sign informed consent * Patients currently under treatment for active TB * Any condition which might, in the investigator's opinion, compromise the safety of the patient by participating in the study, including very severe clinical condition * Person deprived of freedom by a judicial or administrative decision

Contact & Investigator

Central Contact

Marion BONNETON

✉ marion.bonneton@inserm.fr

📞 +84344755013

Principal Investigator

Nicolas NAGOT

PRINCIPAL INVESTIGATOR

PCCI UMR 1058 - INSERM, Univ Montpellier, EFS, Montpellier, Franc

Frequently Asked Questions

Who can join the NCT05655702 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Tuberculosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05655702 currently recruiting?

Yes, NCT05655702 is actively recruiting participants. Contact the research team at marion.bonneton@inserm.fr for enrollment information.

Where is the NCT05655702 trial being conducted?

This trial is being conducted at Haiphong, Vietnam, Haiphong, Vietnam.

Who is sponsoring the NCT05655702 clinical trial?

NCT05655702 is sponsored by ANRS, Emerging Infectious Diseases. The principal investigator is Nicolas NAGOT at PCCI UMR 1058 - INSERM, Univ Montpellier, EFS, Montpellier, Franc. The trial plans to enroll 4,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology